Plimoth Trust’s Teva Pharmaceuticals TEVA Stock Holding History

Plimoth Trust’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-11,845	Closed	-$224K	–	192
2017 Q4	$224K	Buy	+11,845	New	+$178K	0.08%	173

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Plimoth Trust's TEVA Position: Q1 2018 in Review

Plimoth Trust sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 11,845 shares — an estimated $224K sold.

Plimoth Trust first reported a position in TEVA in Q4 2017 and held it in 1 quarter. The position peaked at $224K in Q4 2017. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

Plimoth Trust reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Plimoth Trust sold 11,845 Teva Pharmaceuticals shares in Q1 2018, an estimated $224K.
Plimoth Trust first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Plimoth Trust's Teva Pharmaceuticals position peaked at $224K in Q4 2017.
506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Plimoth Trust's 13F filing for Q1 2018, filed 21 Dec 2018.